Study #2024-0130
Brigatinib plus chemotherapy or local consolidation therapy in ALK positive advanced non-small cell lung cancer (BrightStar-2)
MD Anderson Study Status
Enrolling
Treatment Agent
Brigatinib, Carboplatin, Pemetrexed
Description
The goal of this clinical research study is to learn if the combination of brigatinib and either local consolidation therapy (such as radiotherapy or surgery) or chemotherapy (pemetrexed and carboplatin) can help to control the disease compared with brigatinib alone. The safety of these combinations will also be studied.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Non-small Cell Lung Cancer
Study phase:
Phase II
Physician name:
Yasir Elamin
Department:
Thoracic/Head & Neck Medical Oncology
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.